




ITK Inhibition in T-cell Lymphomas



John Reneau, MD, PhD

ITK Coordinates TCR Signaling





	CPI-818 K _D [*] (nM)
ITK	2.5
BLK	4700
BMX	9100
BTK	1200
EGFR	>10000
ERBB2	>10000
ERBB4	>10000
JAK3	2800
MKK7	>10000
TEC	540
RLK	2700


Preferential ITK Expression in Malignant T Cells




CPI-818 Induces Th1 Skewing in Normal T Cells



Monotherapy Activity in Highly Refractory TCL Patients



Data cut-off: February 2023



ALC Predicts Benefit with CPI-818


ALC Biomarker

- Currently used to select patients in Phase 1/1b clinical trial
- Simple, routine test done on all patients
- ~70% of screened patients meet eligibility requirement
- Consistent with CPI-818 mechanism of action

Supported by Data from Phase 1/1b Trial (200 mg cohort, 13 evaluable patients)

Disease Assessment	ALC < 900 (n = 5)	ALC ≥ 900 (n = 8)
Number Objective Response	0	4
Number Disease Control (CR, PR, SD)	2	8
Median PFS (months)	2.1	28.1
Progression free at 3 months	40%	75%
Progression free at 6 months	20%	60%

ALC Predicts Benefit with CPI-818



Anti-tumor Activity in Refractory Disease

Screening




Day 15




Patient Info

- PTCL-NOS patient failed CHOEP, GDP, HDACi, and anti-PD1
- Large subcutaneous mass on abdomen
- PR 8+ months in all sites of disease (bone marrow, skin, lymph node, and spleen)

Working Model



Working Model



Thank You

John.Reneau@osumc.edu

@LymphomaMD

